LiDCO receives FDA approval for LiDCOplus
Hemodynamic Monitor
14-01-2003
LiDCO, the AIM traded cardiovascular monitoring company, is
pleased to announce that it has received approval from the FDA
(Food and Drug Administration of the USA) for the sale of its
LiDCOplus Hemodynamic Monitor in the USA. The LiDCOplus
has already been certified for sale throughout the European
Union.
The LiDCOplus Hemodynamic Monitor combines the measurement
and monitoring features of the Company's existing products:
the LiDCO (lithium dilution cardiac output measurement) and
PulseCO Systems (real time cardiovascular monitor), thus saving
space around the patient's bed that is at a premium and significantly
enhancing ease of use. The introduction of the LiDCOplus
into the USA market will have a significant impact in expanding
sales.
Dr Terry O'Brien (CEO of LiDCO) commented: " Our PC based equipment
platform allows the rapid and continual evolution of our critical
care monitoring technology. LiDCO believes that, with space
at such a premium around the patient's bed, the combination
of these two separate devices into a single PC based platform
both saves space and significantly enhances the ease of use
of our minimally invasive real time monitor. Improving ease
of use in the operating room and intensive care environments
is key to expanding our equipment market and enhancing use of
the associated disposables. Existing customers who have already
purchased PulseCO monitors can be upgraded to the improved LiDCOplus
functionality by purchasing a software upgrade."
LiDCO Ltd Sales and Marketing, Unit M South Cambridge Business Park, Babraham Road, Sawston, Cambridge CB22 3JH, UK Telephone: +44 (0) 1223 830666 Fax: +44 (0) 1223 837241 VAT number 672 4757 08
